Amendments to the Claims

Please add new Claims 46-49. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Previously presented) A method of treating a patient suffering from or susceptible to an RSV infection, which method comprises administering to said patient an effective amount of a benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

- R^1 represents C_{1-6} alkyl, aryl or heteroaryl;
- R^2 represents hydrogen or C_{1-6} alkyl;
- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $-NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;
- n is from 0 to 3;
- R^4 represents hydrogen or C_{1-6} alkyl;
- R^5 represents C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-

(C_{1-6} hydroxyalkyl)-, heteroaryl-(C_{1-6} hydroxyalkyl)-, carbocyclyl-(C_{1-6} hydroxyalkyl)-, heterocyclyl-(C_{1-6} hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR^6;

- X represents -CO-, -S(O)- or -$S(O)_2$-; and

- R^6 represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-.

2. (Previously presented) A method according to claim 1 wherein:

- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, -CO_2R', -$CONR'R''$, -NH-CO-R', -$S(O)R'$, -$S(O)_2R'$, -NH-$S(O)_2R'$ or -$S(O)NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;

- R^5 represents C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)- or -XR^6;

- X represents -CO-, -S(O)- or -$S(O)_2$-; and

- R^6 represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)- or -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)- or heteroaryl-(C_{1-6} alkyl)-.

3. (Previously presented) A method according to claim 1, wherein R^1 is C_{1-2} alkyl or aryl.

4. (Previously presented) A method according to claim 1, wherein R^2 is hydrogen.

5. (Previously presented) A method according to claim 1, wherein R^3 is halogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino or di(C_{1-4} alkyl)amino.

6. (Previously presented) A method according to claim 5, wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.

7. (Previously presented) A method according to claim 1, wherein R^4 is hydrogen or C_{1-2} alkyl.

8. (Previously presented) A method according to claim 1, wherein R^5 is C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)-, heteroaryl-(C_{1-4} alkyl)-, carbocyclyl-(C_{1-4} alkyl)-, heterocyclyl-(C_{1-4} alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or $-XR^6$.

9. (Previously presented) A method according to claim 8, wherein R^5 is C_{1-4} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-(C_{1-2} alkyl)-, heteroaryl-(C_{1-2} alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or $-XR^6$.

10. (Previously presented) A method according to claim 9, wherein R^5 is C_{1-4} alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH_2-, furanyl-CH_2-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or $-XR^6$.

11. (Previously presented) A method according to claim 1 wherein X is -CO- or -$S(O)_2$-.

12. (Previously presented) A method according to claim 1 wherein, when R^6 is a group -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, aryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)- or heteroaryl-(C_{1-4} alkyl)-.

13. (Previously presented) A method according to claim 12, wherein when R^6 is a group -$NR'R''$ each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-CH_2-.

14. (Previously presented) A method according to claim 13, wherein when R^6 is a group -$NR'R''$ and one of R' and R'' is hydrogen.

15. (Previously presented) A method according to claim 1 wherein R^6 is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-4} alkyl)-, heteroaryl-(C_{1-4} alkyl)-, carbocyclyl-(C_{1-4} alkyl)-, heterocyclyl-(C_{1-4} alkyl)-, aryl-(C_{1-4} hydroxyalkyl)-, heteroaryl-(C_{1-4} hydroxyalkyl)-, carbocyclyl-(C_{1-4} hydroxyalkyl)-, heterocyclyl-(C_{1-4} hydroxyalkyl)-, aryl-(C_{1-4} alkyl)-O-, heteroaryl-(C_{1-4} alkyl)-O-, carbocyclyl-(C_{1-4} alkyl)-O-, heterocyclyl-(C_{1-4} alkyl)-O- or -$NR'R''$.

16. (Previously presented) A method according to claim 15, wherein R^6 is C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocycly, phenyl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} alkyl)-O-, heteroaryl-(C_{1-2} alkyl)-, phenyl-(C_{1-2} hydroxyalkyl)-, heteroaryl-(C_{1-2} hydroxyalkyl)- or -$NR'R''$.

17. (Previously presented) A method according to claim 16, wherein R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl-CH_2-CH(OH)-, phenyl-CH(OH)-CH_2-, phenyl-(C_{1-2} alkyl)-O-, 1*H*-benzo[*d*]imidazol-2(3*H*)-onyl or -$NR'R''$.

18. (Previously presented) A method according to claim 1, wherein the benzodiazepine derivative of formula (I) is a benzodiazepine derivative of formula (Ia):



(Ia)

wherein:

- R^1 is phenyl or methyl;
- R^3 is methyl or chlorine;
- n is 0 or 1;
- R^4 is hydrogen or methyl;
- R^5 is phenyl-CH_2-, furanyl-CH_2-, thienyl-C(O)-C(O)- or -XR^6;
- X is -CO- or -$S(O)_2$-; and
- R^6 is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl-CH_2-CH(OH)-, phenyl-CH(OH)-CH_2-, phenyl-(C_{1-2} alkyl)-O-, 1*H*-benzo[*d*]imidazol-2(3*H*)-onyl or -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-,

the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

the aryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4}

alkyl)amino, di(C_{1-4} alkyl)amino, nitro, $-CO_2R'$, $-S(O)_2R'$ and $-S(O)_2NH_2$, wherein R' represents C_{1-2} alkyl;

the heteroaryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} haloalkyl and di(C_{1-2} alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R^6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl and nitro.

19. (Previously presented) A method according to claim 1, wherein the patient is a child under two years of age.

20. (Previously presented) A method according to claim 19 wherein said child suffers from chronic lung disease.

21. (Previously presented) A method according to claim 1 wherein the patient is an infant less than six years of age who was born after 32 weeks of gestation or less.

22. (Previously presented) A method according to claim 1, wherein the benzodiazepine derivative or salt thereof is administered intranasally or intrabronchially.

23. (Previously presented) A method according to claim 1, wherein an anti-inflammatory compound or an anti-influenza compound is further administered to the patient.

24. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is budesonide or fluticasone.

25. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is a leukotriene antagonist, phosphodiesterase 4 inhibitor or TNF alpha inhibitor.

26. (Previously presented) A method according to claim 23 wherein the anti-inflammatory compound is an interleukin 8 or interleukin 9 inhibitor.

27-30. (Canceled)

31. (Previously presented) An inhaler or nebuliser containing a medicament which comprises
(a) a benzodiazepine derivative of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, and
(b) a pharmaceutically acceptable carrier or diluent.

32. (Previously presented) A product comprising a compound of formula (I), or pharmaceutically acceptable salt thereof, as defined in claim 1, and an anti-inflammatory compound, or an anti-influenza compound.

33. (Previously presented) A method of treating a patient suffering from or susceptible to concomitant RSV and influenza infections, which method comprises administering to said patient an effective amount of a product according to claim 32.

34. (Previously presented) A method of treating a patient suffering from or susceptible to human metapneumovirus, measles, parainfluenza viruses, mumps, yellow fever virus (B5 strain), Dengue 2 virus or West Nile virus, which method comprises administering to said patient an effective amount of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof.

35. (Original) A benzodiazepine derivative of formula (Ib), or a pharmaceutically acceptable salt thereof



(Ib)

wherein:

- R^1 represents C_{1-6} alkyl, aryl or heteroaryl;
- R^2 represents hydrogen, C_{1-6} alkyl;
- each R^3 is the same or different and represents halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, nitro, cyano, $-CO_2R'$, $-CONR'R''$, $-NH-CO-R'$, $-S(O)R'$, $-S(O)_2R'$, $-NH-S(O)_2R'$, $-S(O)NR'R''$ or $-S(O)_2NR'R''$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl;
- n is from 0 to 3;
- R^4 represents hydrogen or C_{1-6} alkyl;
- $R^{5'}$ represents C_{3-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or $-X'$, provided that when $R^{5'}$ is heteroaryl it is not 2-quinaldyl or 6-chloro-pyrazinyl, when $R^{5'}$ is heteroaryl-(C_{1-6} alkyl)- it is not 2-indolylmethyl, 2-(3-indolyl)ethyl or 2-furanylmethyl, when $R^{5'}$ is aryl it is not unsubstituted phenyl and when $R^{5'}$ is aryl-(C_{1-6} alkyl)- it is not unsubstituted phenyl-(C_{1-2} alkyl)- or 4-chlorophenyl-(C_{2-3} alkyl)-;
- X' represents $-CO-R^{6'}$, $-S(O)-R^{6''}$ or $-S(O)_2-R^{6'''}$;
- $R^{6'}$ represents C_1 alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or $-NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl,

aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-, provided that (a) when $R^{6/}$ is aryl it is not unsubstituted naphthyl, unsubstituted phenyl, mono-halophenyl, 4-methylphenyl, 4-methoxyphenyl, 4-hydroxyphenyl, 4-trifluoromethylphenyl, 4-nitrophenyl, 4-cyanophenyl, 4-*n*-propylphenyl, 4-*t*-butylphenyl, 4-*n*-pentylphenyl, 4-dimethylaminophenyl, 4-methylthiophenyl, 3-trifluoromethylthiophenyl, 3,4-dimethoxyphenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,3,4,5,6-pentafluorophenyl, 4-chloro-2-aminophenyl or 4-1,1-dimethylethylphenyl, (b) when $R^{6/}$ is heteroaryl it is not 2-pyrrolyl, 2-pyrazinyl, 2-quinaldyl, 2-quinoxalinyl, 1-methylindonly, 2-methyl-indolyl, 2-benzofuranyl, 2-benzothienyl, 3-thienyl, 3-indolyl, unsubstituted 2-indolyl, 5-fluoroindol-2-yl, 5-chloroindol-2-yl, 5-bromoindol-2-yl, 5-hydroxyindol-2-yl or 5-methoxyindol-2-yl, (c) when $R^{6/}$ is aryl-(C_{1-6} alkyl)- it is not 4-thianaphthene-(CH_2)-, unsubstituted phenyl-(CH_2)-, 4-trifluoromethylphenyl-(CH_2)-, unsubstituted phenyl-$(CH_2)_3$-, monotrifluoromethylphenyl-$(CH_2)_2$-, 3-methoxyphenyl-$(CH_2)_2$-, 4-chloro-2-aminophenyl-$(CH_2)_2$-, 2,4-dichlorophenyl-$(CH_2)_2$-, monochlorophenyl-$(CH_2)_2$-, 2,4-trifluoromethyl phenyl-$(CH_2)_2$-, 4-cyanophenyl-$(CH_2)_2$- or 3-cyanophenyl-$(CH_2)_2$-, (d) when $R^{6/}$ is heteroaryl-(C_{1-6} alkyl)- it is not indolyl-$(CH_2)_x$-, wherein x is 1, 2, 3, unsubstituted furanyl-$(CH_2)_2$-, unsubstituted thienyl-$(CH_2)_3$- (e) when $R^{6/}$ is carbocyclyl it is not cyclohexyl, (f) when $R^{6/}$ is carbocyclyl-(C_{1-6} alkyl)- it is not unsubstituted cyclohexyl-$(CH_2)_{1-3}$-, (g) when $R^{6/}$ is heterocyclyl it is not N-pyrrolidinyl or 2-dihydrobenzofuranyl, (h) when $R^{6/}$ is aryl-(C_{1-6} alkyl)-O- it is not unsubstituted phenyl-(CH_2)-O-, and (i) when $R^{/}$ is hydrogen, $R^{//}$ is not unsubstituted phenyl, 4-halophenyl, 3-halophenyl, methoxyphenyl, nitrophenyl, 2-chlorophenyl, 4-methylphenyl, dichlorophenyl, 3,5-dimethylphenyl, 3-methylphenyl, 3-cyanophenyl, 3-aminophenyl, 3-aminocarbonylphenyl, 3-benzoic acid, 3-benzoic acid ethyl ester, 6-amino-3-pyridyl, 5-(2-chloro)pyridyl, 5-(2-methoxy)pyridyl, 5-indanyl, unsubstituted cyclohexyl, 1,1-dimethylethyl, unsubstituted phenyl-CH_2-, unsubstituted naphthyl or benzotriazol-3-yl and when $R^{/}$ is methyl, $R^{//}$ is not cyclopropylbenzene;

- $R^{6//}$ represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6}

alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR^{/}R^{//}$ wherein each $R^{/}$ and $R^{//}$ is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-,; and

- $R^{6///}$ represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR^{/}R^{//}$ wherein each $R^{/}$ and $R^{//}$ is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-, provided that when $R^{6///}$ is aryl it is not 4-methylphenyl, provided that the compound of formula (Ib) is not N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.

36. (Original) A benzodiazepine derivative according to claim 35 wherein:

- $R^{5/}$ is C_{3-6} alkyl, C_{3-6} cycloalkyl, heterocyclyl, C_{3-6} cycloalkyl-(C_{1-6} alkyl), aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -$X^{/}$;
- $X^{/}$ is -CO-$R^{6/}$, -S(O)-$R^{6//}$ or -$S(O)_2$-$R^{6///}$;
- $R^{6/}$ is C_1 alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, heterocyclyl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR^{/}R^{//}$ wherein each $R^{/}$ and $R^{//}$ is the same or different and represents hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, heterocyclyl, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-;
- $R^{6//}$ represents C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR^{/}R^{//}$ wherein each $R^{/}$ and $R^{//}$ is the same or different and represents hydrogen, C_{1-3} alkyl, heterocyclyl, heteroaryl, heteroaryl-(C_{1-6} alkyl)-, carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-; and

- $R^{6'''}$ is C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{3-6} cycloalkyl, heterocyclyl, C_{3-6} cycloalkyl-(C_{1-6} alkyl)-, heterocyclyl-(C_{1-6} alkyl)-, aryl-(C_{1-6} alkyl)-O-, heteroaryl-(C_{1-6} alkyl)-O-, carbocyclyl-(C_{1-6} alkyl)-O-, heterocyclyl-(C_{1-6} alkyl)-O- or -$NR'R''$ wherein each R' and R'' is the same or different and represents hydrogen, C_{1-6} alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C_{1-6} alkyl)-, heteroaryl-(C_{1-6} alkyl), carbocyclyl-(C_{1-6} alkyl)- or heterocyclyl-(C_{1-6} alkyl)-.

37. (Previously presented) A benzodiazepine derivative according to claim 35 wherein R^2 is hydrogen.

38. (Original) A benzodiazepine derivative of formula (Ic), or a pharmaceutically acceptable salt thereof,



(Ic)

wherein:

- R^1 is phenyl or methyl;
- R^3 is methyl or chlorine;
- n is 0 or 1;
- R^4 is hydrogen or methyl;
- $R^{5'}$ is phenyl-CH_2- thienyl-C(O)-C(O)- or -X';
- X' is -CO-$R^{6'}$, -CONR'R'', -$S(O)_2R^{6'''}$ or -$S(O)_2$-$NR'R''$; and
- $R^{6'}$ is C_1 alkyl, C_{1-4} alkoxy, benzodioxinyl, 9H-fluoren-9-onyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, cyclopentyl, piperazinyl, piperidinyl, morpholinyl, phenyl-CH_2-CH(OH)-, phenyl-CH(OH)-CH_2-, phenyl-(C_2 alkyl)-O- or 1*H*-benzo[*d*]imidazol-2(3*H*)-only;

- $R^{6''''}$ is C_{1-4} alkyl, C_{1-4} alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C_{1-2} alkyl)-, phenyl-CH_2-CH(OH)-, phenyl-CH(OH)-CH_2-, phenyl-(C_{1-2} alkyl)-O- or 1*H*-benzo[*d*]imidazol-2(3*H*)-only;
- each R' and R'' is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-; and
- each $R_/$ and $R_{//}$ is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH_2)-, wherein:

the phenyl moiety in the group R^1 being unsubstituted or substituted by a single fluorine, chlorine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl or C_{1-2} haloalkoxy substituent;

the aryl moieties in the groups $R^{5'}$, $R^{6'}$ and $R^{6''''}$ being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C_{1-4} alkyl, C_{2-4} acyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-6} haloalkyl, C_{1-4} haloalkoxy, amino, mono(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino, nitro, $-CO_2R'$, $-S(O)_2R'$ and $-S(O)_2NH_2$, wherein R' represents C_{1-2} alkyl;

the heteroaryl moieties in the groups $R^{5'}$, $R^{6'}$ and $R^{6''''}$ being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} haloalkyl and di(C_{1-2} alkyl)amino;

the heterocyclyl and carbocyclyl moieties in the $R^{6''''}$ group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl and nitro;

the aryl, heteroaryl and carbocyclyl moieties in the R' and R'' being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl and nitro; and

the aryl, heteroaryl and carbocyclyl moieties in the $R_/$ and $R_{//}$ being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl and nitro,

provided that the compound of formula (Ic) is not N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide.

39. (Original) A benzodiazepine derivative of formula (Id), or pharmaceutically acceptable salts thereof



(Id)

wherein R^{6*} is an aryl group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C_{1-6} alkyl, C_{2-7} acyl, hydroxy, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, nitro, cyano, carbamoyl, mono(C_{1-6} alkyl)carbamoyl, di(C_{1-6} alkyl)carbamoyl, amino, mono(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, $-CO_2R'$, $-CONR'R''$, $-S(O)R'$, $-S(O)_2R'$, $-S(O)NR'R''$, $-S(O)_2NR'R''$ $-NH-S(O)_2R'$ or $-NH-CO-R'$, wherein each R' and R'' is the same or different and represents hydrogen or C_{1-6} alkyl, provided that R^{6*} is not a 4-chlorophenyl group.

40. (Original) A benzodiazepine derivative of formula (Ie) or a pharmaceutically acceptable salts thereof



(Ie)

wherein R'* is an aryl group which is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy and nitro.

41. (Original) 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide

2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide

Cyclopentanecarboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

4-Methyl-piperazine-1-carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide

Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

Butane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isobutyramide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide

(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester

5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamic acid methyl ester

2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

(S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide

2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sylfamoyl-benzamide

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Cycloheyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea

4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide

Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide

Cyclohexanecarboxylic acid [5-(3chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide

Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide

2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester

(S)-6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid isobutyl ester

2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide,

or a pharmaceutically acceptable salt thereof.

42. (Canceled)

43. (Previously presented) A pharmaceutical composition comprising a benzodiazepine derivative according to Claim 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier.

44. (Previously presented) A composition comprising an optically active isomer of a benzodiazepine derivative according to Claim 31.

45. (Previously presented) A composition according to claim 43 which is in the form of a tablet, troche, lozenge, aqueous or oily suspension, dispersible powders or granules.

46. (New) A process for preparing a benzodiazepine derivative of the formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting 2-amino-benzophenone with bromoacetyl bromide, or an equivalent reagent, followed by ring closure with ammonia;

(b) protecting the NH group on the thus obtained compound by reacting with a base and an alkylating agent;

(c) reacting the protected intermediate thereby obtained with a base in a suitable solvent, to obtain thereby an oxime intermediate;

(d) converting the thus obtained oxime intermediate into a corresponding racemic primary amine;

(e) carrying out dynamic kinetic resolution on the racemic amine in the presence of a suitable optically active acid and a suitable aldehyde to precipitate a salt of the (S)-amine.

47. (New) A process according to claim 46, which further comprises:

(f) transforming the optically active amine obtained in step (e) into an amide or urea.

48. (New) A process according to claim 46 wherein the protecting group introduced in step (b) is 4-methoxy-benzyl.

49. (New) A process according to claim 46, wherein the benzodiazepine derivative of the formula (I) is (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea or (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.